We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ark Ther Grp | AKT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 63.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 63.25 | 63.25 |
| Top Posts |
|---|
Posted at 01/3/2015 16:36 by hedgehog 100 EJ,The directors here do seem to be very good at looking after themselves. They allowed themselves to invest in the placing at 10.1p, a discount of over 80% to the suspended share price consolidation-adjust Normal retail shareholders did not have that opportunity. And after the first day of trading back from suspension on Friday, the share price is now at 28.5p. And it was announced late in Friday afternoon trading that they have granted two of themselves options at 10.1p: 27/02/2015 16:07 UKREG Ark Therapeutics Group PLC Board Changes and Directors' Dealings London, UK, 27 February 2015 (LSE: AKT): The Company announces that it has today issued options to subscribe for new ordinary shares of 10 pence each in its capital, including awards to the following Directors: Name Role Number of options Exercise price per share --------------- -------------------- -------------------- Dominic Tonner Director (Chief 279,035 10.1 pence Executive Officer) --------------- -------------------- -------------------- Daniel Smith Director (Chief 209,277 10.1 pence Financial Officer) --------------- -------------------- -------------------- Each of the above options was granted pursuant to the 2014 Ark Therapeutics Group plc Enterprise Management Incentive Share Option Plan. As outlined in the Circular issued to Shareholders on 21 November 2014 (the "Circular") and the Prospectus published on 26 February 2015 (the "Prospectus"), the options were granted at an exercise price equal to the Subscription Price (as defined in the Circular and the Prospectus) of 10.1 pence, and will vest in full on the later of the first anniversary of the date of grant and the date that the market price of an ordinary share is at least twice the Subscription Price, and has been for a continuous period for 15 days. No consideration was paid for the grant of options. ... " |
Posted at 28/1/2015 17:14 by hedgehog 100 28/01/2015 09:29 UKREG Ark Therapeutics Group PLC Sale and Purchase Agreement Signed"Sale and Purchase Agreement Signed London, UK, 28 January 2015 (LSE: AKT): Ark Therapeutics Group plc ("Ark" or the "Company") announces that, as foreshadowed in the Company's announcement and in its circular to shareholders, in each case dated 21 November 2014, it has entered into a share sale and purchase agreement with Rajan Uppal, Dominic Tonner and Berkeley Burke Trustee Company Limited to acquire 75.8% of the issued share capital of Premier Veterinary Group Limited ("PVG"). The aggregate consideration payable to all PVG shareholders is GBP3,731.18 in cash. The sellers have invoked the drag-along provisions contained in PVG's articles of association to enable the Company to acquire the entire issued share capital of PVG. Completion of the acquisition is scheduled to occur on 5 February 2015. The Company's shares will remain suspended until further notice but, as set out in the circular of 21 November 2014, it is the intention of the Company to publish a prospectus and to seek readmission of the Company's shares on the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. A further announcement will be made in due course." Though completion of the acquisition is due next week (Thursday), they don't say that the prospectus will be published then, and until that happens the suspension can't be lifted. As AKT is main-listed rather than AIM-listed, there is no time-limit for the suspension period (AIM has a 6-month limit). |
Posted at 21/1/2015 16:21 by hedgehog 100 On or around today:21/11/2014 17:48 UKREG Ark Therapeutics Group PLC Posting of Circular "10. Expected timetable of principal events Time and/or date ... Date upon which cancellation of the 14 January 2015 premium listing category will become effective Expected date of completion of the on or around 20 January Acquisition 2015 Expected date of publication of the on or around 21 January Prospectus 2015 ... The transfer from the official list has gone ahead, so I would expect further news imminently: 15/01/2015 07:00 UKREG Ark Therapeutics Group PLC Transfer of listing category on the Official List "London, UK, 15 January 2015 (LSE: AKT): Ark Therapeutics Group plc ("Ark" or the "Company") announces that, following the passing of the relevant resolution by its shareholders at the Company's General Meeting on 11 December 2014, the Company's listing category will be transferred from "premium listing (commercial company)" to "standard listing" as of 8.00 am today. The Company's ordinary shares will remain suspended pending the publication of a prospectus in relation to the proposed acquisition of Premier Veterinary Group Limited, which constitutes a reverse takeover." |
Posted at 03/11/2014 15:33 by ten bag man AKT came to the market with a valuation of £170MIt would be rather nice if it could get back their in the next few years. It fell 99.6%.!! UCL spin-out company Ark Therapeutics floated on Stock Exchange Publication date: Mar 13, 2006 4:04:08 PM The healthcare group Ark Therapeutics Ltd, a UCL spin-out company, has today been floated on the London Stock Exchange. The company was founded by Professor John Martin in UCL’s Department of Medicine, and specialises in developing products targeted at vascular disease and cancer. The value of the company on the Stock Exchange today is approximately £170 million, and its flotation is the first of a biotech company in Europe for two years. Professor Martin said: “I hope the flotation of Ark Therapeutics on the London Stock Exchange as a public company will encourage other academics to examine what intellectual property they can generate from their research. I had the initial idea in 1997, and now, under seven years later, we have a public company with five products in clinical trials. Founding a biotech company can bring reward to the university and bring about benefit to society. It is fulfilling to see your research ideas go all the way to clinical application.” Jeff Skinner, Commercial Director of UCL Business, said: “The IPO market has been closed for so long that this has seriously affected university spin-out activity. I’m delighted that Ark Therapeutics has floated successfully – it’s a great company and its success will help to restore confidence in the entire sector.” |
Posted at 03/11/2014 12:05 by ten bag man Significant minority:From the WWW. "A minority is anything below 50% of a group. An insignificant minority will be a minority so small it doesn't really matter, while a significant minority will be something like 30% of a group. Clearly not the majority but big enough to be important for whatever purpose you're using it for." 30% sounds about right to me. My sums are based on this 30%(it could be higher or lower than 30%, time will no doubt tell)! If,(and it's a big if) this is in the ball park then here are some of my ideas. AKT shares stopped trading on March 28th 2014 @0.524p with a market cap of £1.2M Just for that value to stay the same of the first day of dealing the new company would have to have a market cap of around £4M Anything under £4M and old AKT shareholders will be making a loss (Based on the share price of 28th March 2014. So here we go. Market cap on first day of dealing. £4M break even. Then each extra Million pounds of market cap should I think give ARK shareholders and extra 30% on top of the £1.2M market cap on March 28th 2014. Thus: Each extra million of market cap gives AKT shareholders an extra £300,000 If the market cap on the first day of dealing was £14M AKT shareholders should be better off to the tune of £3M pounds. The share price would then be up 250%. |
Posted at 03/11/2014 08:39 by ten bag man AKT shares traded at 0.345P at the start of 2014.The directors paid ten times that amount for stock,so just to get their cash back they require a massive jump in the share price. (10 x) The only way to do that,(in my view)is to do an RTO. The RNS OF THE 28th of March 2014 tells shareholders the plan is to pick up a lump of the new companies shares in exchange for the FULL PREMIUM listing AKT has. That in itself is pointing to an instant gain for AKT shareholders. In effect part of the new company is to be given to us.!(if the RTO goes through) On top of this we will then be shareholders in the NEW company. That new company would have wanted to come to the London Stock Market for a reason. |
Posted at 03/11/2014 07:20 by ten bag man In the case of AKT.It is PREMIUM listed on the London Stock Exchange. Might want to look that up.! Note also the track record of the directors and the funding for over £250M they have bought to the market. Then take a look at the large shareholders,heaps of top city names inc Standard Life. AKT has stated for the last 18 months that it intends to do an RTO or hand back the cash in the company to shareholders. |
Posted at 02/5/2014 17:49 by buywell2 These are cast in legal stoneOnly tax losses for the previous three years can be used to offset future income. And A merger may not be structured solely for tax purposes. Has some investor looked at what the last 3 years AKT tax losses add up to ? |
Posted at 30/4/2014 22:16 by hedgehog 100 30/04/2014 07:01 UKREG Ark Therapeutics Group PLC Final Results"London, UK, 30 April 2014- Ark Therapeutics Group plc (LSE: AKT) today announces its audited results for the year ended 31 December 2013. Financial highlights -- Total revenues and other income for the year ended 31 December 2013 of GBP0.3m (31 December 2012: GBP1.9m) -- Net assets at 31 December 2013 of GBP0.9m (31 December 2012: net liabilities of GBP0.2m) -- Cash and short-term deposits of GBP0.8m (31 December 2012: GBP1.7m) -- Profit for the year after tax was GBP1.1m (31 December 2012: loss after tax was GBP2.5m) -- On 15 March 2013 the Company disposed of its operating subsidiaries - - Post-period the Company signed heads of terms in connection with the possible acquisition of a revenue-generating and profitable UK-based private company in the healthcare support services sector A full copy of the Company's Annual Report and Accounts for the year ended 31 December 2013 is available on its website at www.arktherapeutics. Disclosure & Transparency Rule ("DTR") 6.3.5 requires the Company to disclose to the media certain information from its Annual Report, if that information is of a type that would be required to be disseminated in a half-yearly report. Accordingly, this announcement should be read in conjunction with and is not a substitute for reading, the full Annual Report and Accounts. Together these constitute the information required by DTR 6.3.5, which is required to be communicated in unedited full text through a Regulatory Information Service. The information included in this announcement is extracted from the 2013 Annual Report which was approved by the Directors on 29 April 2014. Defined terms used in the announcement refer to terms as defined in the 2013 Annual Report unless the context otherwise requires. Annual General Meeting The Notice convening the next Annual General Meeting, which is expected to take place by the end of June 2014 at the offices of Ashurst, Broadwalk House, 5 Appold Street, London EC2A 4HA will be posted separately to shareholders nearer the time. For further information please contact: Ark Therapeutics Group plc Tel: +44 (0)207 002 1005 Iain G Ross, Non-Executive Chairman David Venables, Non-Executive Director " |
Posted at 26/3/2014 08:41 by tara7 If a big biotech comes in for AKT Your looking at one hell of a deal.Mr Ross is just such a deal maker and has in the past raised over £20M. He is also a director of COMS and has shown to have done very very well their in the past year. His shares have I think seen a ten fold rise. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
